Divi's Laboratories Limited (DIVISLAB) — Financial Results | 3 February 2025(3 announcements)

Divi's Laboratories reported consolidated total income of ₹2401 crores for Q3 FY25, up 23% YoY from ₹1950 crores, with profit before tax at ₹726 crores (+48% YoY) and profit after tax at ₹589 crores (+64% YoY). Standalone revenue reached ₹2379 crores for the quarter and ₹6927 crores for nine months, reflecting strong operational growth. The company approved Dr. Kiran S. Divi's reappointment as Whole-time Director and CEO for five years effective April 1, 2025, subject to shareholder approval via postal ballot. Capex capitalization for the Kakinada project reached ₹418 crores in nine months, with full commercial operations expected within six months.

Divi's Laboratories reported a 32% YoY jump in quarterly revenue to ₹2,379 crores and a 69.9% YoY rise in net profit to ₹594 crores for Q3 FY25, driven by strong domestic and export demand. The company highlighted new commercial operations in Andhra Pradesh and tax optimisation under Section 115BAA. Shareholders gain from robust profit growth and expanded manufacturing capacity.

Divi's Laboratories reported consolidated net profit of ₹87.22 crores for Q3 FY25, up 32% YoY from ₹65.98 crores in Q3 FY24, driven by strong revenue growth to ₹1,215.5 crores (+19% YoY). The company highlighted robust performance across key therapeutic segments and maintained healthy margins despite foreign exchange volatility.